{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:31:50Z","timestamp":1793457110424,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University","id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prolactinomas are the commonest pituitary adenoma encountered in clinical practice, yet many aspects of their assessment and management remain variable. The 2023 Pituitary Society Consensus Statement on the diagnosis and management of prolactin-secreting pituitary adenomas provided important contemporary guidance, but the extent to which current practice aligns with these recommendations remains unclear. We aimed to define international multidisciplinary perspectives on resource availability and clinical decision-making in prolactinoma care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an international cross-sectional survey of endocrinologists and neurosurgeons involved in prolactinoma management. Questions examined access to clinical resources, awareness of emerging issues in prolactinoma care, and areas of concordance or discordance between reported practice and published guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 249 clinicians completed the survey, including 210 endocrinologists and 39 neurosurgeons, from America, Europe, Oceania and Asia. Important resource limitations included inconsistent reporting of Knosp grade and limited availability of transcription factor immunohistochemistry. Only 20% of respondents routinely referred newly diagnosed prolactinoma cases for multidisciplinary team discussion. Most endocrinologists counselled patients regarding dopamine agonist-related risks. Amongst neurosurgeons, reported indications for surgery and views on dopamine agonist-induced tumour fibrosis varied considerably. Although current guidelines support surgery as an equal first-line option in selected microadenomas, cabergoline remained the preferred initial treatment in these scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>International prolactinoma practice is heterogeneous and often discordant with contemporary guidance. Most notably, cabergoline therapy remains the preferred treatment strategy in microprolactinomas, and multidisciplinary discussion of prolactinoma cases is infrequent. This survey dataset serves as a roadmap for future research and clinical service improvement in prolactinoma care globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01757-8","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:21:26Z","timestamp":1789586486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6482","authenticated-orcid":false,"given":"Sunita M. C.","family":"De Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani J.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Ovenden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Prevedello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"12","key":"1757_CR1","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769\u20134775","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1757_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1757_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1757_CR4","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1136\/jmg.40.5.e72","volume":"40","author":"A Cebri\u00e1n","year":"2003","unstructured":"Cebri\u00e1n A, Ruiz-Llorente S, Cascon A, Pollan M, Diez J, Pico A, Telleria D, Benitez J, Robledo M (2003) Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients. J Med Genet 40(5):e72","journal-title":"J Med Genet"},{"issue":"1","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-13-0623","volume":"170","author":"TG Papathomas","year":"2014","unstructured":"Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, Bayley JP, Morreau H, van Dooren M, Papaspyrou K, Schreiner T, Hansen T, Andresen PA, Restuccia DF, van Kessel I, van Leenders GJ, Kros JM, Looijenga LH, Hofland LJ, Mann W, van Nederveen FH, Mete O, Asa SL, de Krijger RR, Dinjens WN (2014) Non-pheochromocytoma (PCC)\/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 170(1):1\u201312","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1757_CR6","doi-asserted-by":"publisher","first-page":"E710","DOI":"10.1210\/jc.2014-4297","volume":"100","author":"P Xekouki","year":"2015","unstructured":"Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, Mastorakos P, Wassif CA, Raygada M, Rentia N, Dye L, Cougnoux A, Koziol D, Sierra Mde L, Lyssikatos C, Belyavskaya E, Malchoff C, Moline J, Eng C, Maher L, Pacak K, Lodish M, Stratakis C (2015) Pituitary Adenoma With Paraganglioma\/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice. J Clin Endocrinol Metab 100(5):E710\u2013E719","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1757_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1210\/clinem\/dgaa957","volume":"106","author":"AJ Seabrook","year":"2021","unstructured":"Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T, Hockings JI, Hockings NG, Kirk J, Leo PJ, Love AJ, Luxford C, Marshall M, Mete O, Pennisi DJ, Brown MA, Gill AJ, Hockings GI, Clifton-Bligh RJ, Duncan EL (2021) Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? J Clin Endocrinol Metab 106(4):1163\u20131182","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1757_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1210\/er.2012-1013","volume":"34","author":"A Beckers","year":"2013","unstructured":"Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239\u2013277","journal-title":"Endocr Rev"},{"issue":"1","key":"1757_CR9","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EO-21-0038","volume":"2","author":"SMC De Sousa","year":"2022","unstructured":"De Sousa SMC (2022) Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocr Oncol 2(1):R31\u2013r50","journal-title":"Endocr Oncol"},{"key":"1757_CR10","doi-asserted-by":"crossref","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol19(12):722\u2013740","DOI":"10.1038\/s41574-023-00886-5"},{"issue":"3","key":"1757_CR11","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G (2004) Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 6(3):e34","journal-title":"J Med Internet Res"},{"issue":"5","key":"1757_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A, Pituitary Society Expert Group on Pituitary Tumors (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 20(5):489\u2013498","journal-title":"Pituitary"},{"issue":"3","key":"1757_CR13","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"Luger A, Broersen LHA, Biermasz NR, Biller BMK, Buchfelder M, Chanson P, Jorgensen JOL, Kelestimur F, Llahana S, Maiter D, Mintziori G, Petraglia F, Verkauskiene R, Webb SM, Dekkers OM (2021) ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol 185(3):G1\u2013g33","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1757_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/cen.13940","volume":"90","author":"R Steeds","year":"2019","unstructured":"Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W (2019) Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf) 90(5):662\u2013669","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1757_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13643-024-02738-3","volume":"14","author":"J Schifano","year":"2025","unstructured":"Schifano J, Niederberger M (2025) How Delphi studies in the health sciences find consensus: a scoping review. Syst Rev 14(1):14","journal-title":"Syst Rev"},{"issue":"4","key":"1757_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11102-022-01246-8","volume":"25","author":"V Raverot","year":"2022","unstructured":"Raverot V, Perrin P, Chanson P, Jouanneau E, Brue T, Raverot G (2022) Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary 25(4):653\u2013657","journal-title":"Pituitary"},{"issue":"4","key":"1757_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521\u2013535","journal-title":"Acta Neuropathol"},{"key":"1757_CR18","doi-asserted-by":"publisher","first-page":"124826","DOI":"10.1016\/j.wneu.2026.124826","volume":"207","author":"C De Ovenden","year":"2026","unstructured":"Ovenden C, Tan V, Torpy DJ, Chapman I, Saran F, Jukes A, Santoreneos S, Vrodos N, Poonnoose S, Candy N, Psaltis A, De Sousa SMC (2026) Surgical outcomes in knosp grade 3 or 4 macroprolactinomas. What role does debulking surgery play? World Neurosurg 207:124826","journal-title":"World Neurosurg"},{"key":"1757_CR19","doi-asserted-by":"crossref","unstructured":"Spuler K, White R, Lim WT, Deeb J, McNeil J, Bouras G, Jukes A, Santoreneos S, Psaltis A, Patel S, De Sousa SMC (2026) A Retrospective cohort study of Knosp grade reporting of cavernous sinus invasion in pituitary macroadenomas. Pituitary 29(3):78","DOI":"10.1007\/s11102-026-01683-9"},{"issue":"1","key":"1757_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33(1):6\u201326","journal-title":"Endocr Pathol"},{"issue":"3","key":"1757_CR21","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2019","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J, Thompson T, McCormack AI, Inder WJ, Torpy DJ (2019) Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab 105(3):e108\u2013e118","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1757_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SM De Sousa","year":"2017","unstructured":"De Sousa SM, Chapman IM, Falhammar H, Torpy DJ (2017) Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 55(2):618\u2013624","journal-title":"Endocrine"},{"issue":"3","key":"1757_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-025-01517-0","volume":"28","author":"R Hamblin","year":"2025","unstructured":"Hamblin R, White M, Fountas A, Karavitaki N (2025) Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre. Pituitary 28(3):52","journal-title":"Pituitary"},{"issue":"2","key":"1757_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265\u2013273","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1757_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1757_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-023-01309-4","volume":"26","author":"VR van Trigt","year":"2023","unstructured":"van Trigt VR, Pelsma ICM, Biermasz NR (2023) Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need. Pituitary 26(3):307\u2013317","journal-title":"Pituitary"},{"issue":"5","key":"1757_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41574-024-00976-y","volume":"20","author":"SMC De Sousa","year":"2024","unstructured":"De Sousa SMC, Jukes AK, Candy NG, Chapman IM, Torpy DJ, Shivalingam B, Wormald PJ, Santoreneos S (2024) Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern. Nat Rev Endocrinol 20(5):314","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1757_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-025-01628-8","volume":"29","author":"AN Mamelak","year":"2026","unstructured":"Mamelak AN, Fox R, Rosenberg Y, Gomez D, Cui Y, Shlomo AB, Labadzhyan A, Liu NA, Bonert V, Cooper O (2026) Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes. Pituitary 29(1):27","journal-title":"Pituitary"},{"issue":"1","key":"1757_CR29","first-page":"e220086","volume":"3","author":"AG Hayes","year":"2023","unstructured":"Hayes AG, Shirazi MG, Thiyagarajah A, Torpy DJ, De Sousa SMC (2023) Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocr Oncol 3(1):e220086","journal-title":"Endocr Oncol"},{"issue":"4","key":"1757_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF (2024) Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary 27(4):381\u2013388","journal-title":"Pituitary"},{"issue":"5","key":"1757_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, Strasburger C, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583\u2013596","journal-title":"Pituitary"},{"issue":"4","key":"1757_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11102-024-01416-w","volume":"27","author":"S Grottoli","year":"2024","unstructured":"Grottoli S, Ghigo E (2024) Pituitary tumor centers of excellence (PTCOE): the next border of acromegaly treatment. Pituitary 27(4):314\u2013316","journal-title":"Pituitary"},{"issue":"5","key":"1757_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11102-023-01348-x","volume":"26","author":"E Jouanneau","year":"2023","unstructured":"Jouanneau E, Calvanese F, Ducray F, Raverot G (2023) Pituitary Tumor Centers of Excellence (PTCOE) should now include neuro-oncologic input. Pituitary 26(5):642\u2013643","journal-title":"Pituitary"},{"key":"1757_CR34","doi-asserted-by":"crossref","unstructured":"Yagci AN, Pekmezci A, Uygur MM, Burhan S, Celik M, Aktas Yagci F, Tuna MM, Niyazoglu M, Hatipoglu E (2026) Patient-reported outcomes in a pituitary tumor center of excellence (PTCOE)-aligned pituitary clinic compared with general endocrinology care. Pituitary 29(3):90","DOI":"10.1007\/s11102-026-01692-8"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01757-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:12:03Z","timestamp":1793455923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01757-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"156"}}